December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Tissue Plasminogen Activator in Treatment of Submacular Hemorrhage
Author Affiliations & Notes
  • S Loon
    Ophthalmology National University Hospital Singapore Singapore
  • c CHEE
    Ophthalmology NATIONAL UNIVERSITY HOSPITAL Singapore Singapore
  • Footnotes
    Commercial Relationships   S. Loon, None; C. Chee, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3497. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S Loon, c CHEE; Tissue Plasminogen Activator in Treatment of Submacular Hemorrhage . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3497.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: We investigated the use of intravitreal tPA (tissue plasminogen activator) to clear submacular hemorrhage. Methods: 20 consecutive patients were evaluated Retrospectively. The causes for submacular haemorrhage included age related macular degeneration (ARMD) (3 cases),idiopathic polypoidal choroidal vasculopathy (IPCV)(15 cases), and trauma (1 case) and macroaneurysm (1 case). All cases underwent intravitreal injection of tPA and perfluoropropane by a single surgeon with prone positioning post operatively to displace submacular blood. Results: Submacular blood was successful displaced in all cases. 50% achieved 6/12 vision or better. Treatment within 2 weeks of symptoms was associated with better visual outcome. Complications included retinal detachment (3 cases)and glaucoma requiring treatment (1 case). Conclusion: tPA is useful in treating submacular haemorrhage. Visual outcome is better when the procedure is performed within 2 weeks of the submacular haemorrhage.

Keywords: 554 retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.